Q2 saw strong sales and record backlog, with all segments growing and robust international demand. Guidance for 2026 was raised for sales, EPS, and book-to-bill, supported by major program wins and continued investment in capacity and innovation.

Based on

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.